10-K: Leap Therapeutics Reports Full Year 2023 Results, Highlights Clinical Progress

Leap Therapeutics' 2023 annual report details significant R&D spending, clinical trial advancements, and a net loss, while emphasizing the potential of their drug candidates.

Summary

• Leap Therapeutics, a biopharmaceutical company, reported a net loss of $81.4 million for the year ended December 31, 2023, and an accumulated deficit of $399.6 million.
• The company's research and development expenses totaled $73.2 million in 2023, compared to $45.0 million in 2022, primarily due to the acquisition of in-process R&D from Flame Biosciences.
• The company is focused on developing biomarker-targeted antibody therapies, with lead candidates DKN-01 and FL-301 in clinical trials.
• DKN-01 is being studied in esophagogastric, gynecologic, and colorectal cancers, while FL-301 targets Claudin18.2-expressing cells.
• The company anticipates initial ORR data from Part C of the DisTinGuish study in mid-2024 and preliminary PFS data in the second half of 2024.
• Enrollment in Part B of the DeFianCe study is expected to be completed in mid-2024.
• The company believes its current cash and cash equivalents will fund operations for at least the next 12 months.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive clinical trial results and strategic partnerships, the significant net loss and reliance on future funding create uncertainty. The sentiment is neutral to slightly negative.

Positives

• DKN-01 demonstrated promising response rates in early clinical trials, particularly in DKK1-high patient subgroups.
• The company has multiple ongoing clinical trials for DKN-01 across different cancer types.
• FL-301 has received orphan drug designation for gastric, gastroesophageal junction, and pancreatic cancers.
• The company has a strategic partnership with BeiGene for the DisTinGuish trial and with NovaRock for FL-301 and FL-302.
• The company has a collaboration agreement with Adimab for the development of FL-501.
• The company has a strong intellectual property portfolio with patents and applications related to DKN-01 and FL-301.

Negatives

• The company reported a significant net loss of $81.4 million for 2023.
• The company has an accumulated deficit of $399.6 million.
• The company has no products approved for sale and has not generated any revenue from product sales.
• The company is dependent on third-party contract manufacturers for clinical trial material.
• The company is subject to the risk of clinical trial delays and failures.
• The company faces competition from larger pharmaceutical and biotechnology companies.

Risks

• The company's future success is heavily dependent on the success of DKN-01.
• Clinical trials are expensive and can take many years to complete, with uncertain outcomes.
• The company may not be able to obtain regulatory approvals for its product candidates.
• The company may experience delays in patient enrollment for clinical trials.
• The company relies on third parties for manufacturing and clinical trial management.
• The company may require additional capital to fund its operations.
• The company's share price has been low and volatile.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future as it continues the development of its product candidates and seeks regulatory approvals. The company believes its current cash and cash equivalents will fund operations for at least the next 12 months.

Management Comments

• The company intends to apply its extensive experience identifying and developing transformational products to build a pipeline of programs that have the potential to change the practice of cancer medicine.

Industry Context

The biotechnology and pharmaceutical industries are characterized by continuing technological advancement and significant competition. Leap Therapeutics faces competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. The company is focused on developing novel therapies for cancer, a disease with a high unmet medical need.

Comparison to Industry Standards

• The reported net loss of $81.4 million is typical for a clinical-stage biopharmaceutical company with no approved products.
• The increase in R&D spending to $73.2 million reflects the company's commitment to advancing its clinical programs, which is consistent with industry trends for companies in similar stages of development.
• The reported ORR of 73% in Part A of the DisTinGuish study is competitive with other combination therapies in gastric cancer.
• The 55% ORR in dual biomarker-high patients in Part B of the DisTinGuish study is promising and suggests a potential for targeted therapy.
• The 30% ORR and 93% DCR in Part A of the DeFianCe study are comparable to other second-line treatments for colorectal cancer.
• The company's reliance on third-party CMOs is a common practice in the biopharmaceutical industry, especially for companies without their own manufacturing facilities.
• The company's focus on biomarker-targeted therapies aligns with the industry trend towards personalized medicine.

Related Party Transactions

• The company has a license agreement with Eli Lilly and Company, a shareholder.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• Employees are subject to the company's performance and financial stability.
• Patients may benefit from the development of new cancer therapies.
• Creditors face the risk of the company's financial instability.

Next Steps

• The company expects to have initial ORR data from Part C of the DisTinGuish study in mid-2024.
• The company expects to have preliminary PFS data from Part C of the DisTinGuish study in the second half of 2024.
• The company expects to complete enrollment in Part B of the DeFianCe study in mid-2024.

Key Dates

Keywords

DKN-01, FL-301, cancer therapy, clinical trials, biopharmaceutical, antibody, oncology, DKK1, Claudin18.2, research and development